Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Trypan Blue

FDA-approved product (solution, ophthalmic), marketed as Membraneblue, Visionblue.

Registered studies
23
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Trypan Blue
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Trypan Blue. Its therapeutic class is shown instead.

WHO therapeutic group
Other surgical aids
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli31.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

23registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Trypan Blue in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Trypan Blue with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy of Lutein, Zeaxanthine and Trypan Blue to Stain the Anterior Lens Capsule

    NCT01621789 · start 2012-06

    Registered record
    Registry ID
    NCT01621789
    Conditions
    Cataract
    Interventions
    dye of lutein, zeaxanthin, trypan blue
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-06
    Completion
    2014-05
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCataract
    Interventiondye of lutein, zeaxanthin, trypan blue
    PhasePhase 3
    Registry statusCompleted

  • Mechanical Properties of the Internal Limiting Membrane and Intraoperative Utility of Brilliant Blue g (Bbg) and Indocyanine Green (Icg) Assisted Chromovitrectomy

    NCT01485575 · start 2011-11

    Registered record
    Registry ID
    NCT01485575
    Conditions
    Macular Edema
    Interventions
    Use of intraoperative filters in vitrectomy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2011-11
    Completion
    2028-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Edema
    InterventionUse of intraoperative filters in vitrectomy
    PhaseNot recorded
    Registry statusRecruiting

  • Inverted ILM Repositioning as Treatment for Full Thickness Macular Holes

    NCT01228188 · start 2010-08

    Registered record
    Registry ID
    NCT01228188
    Conditions
    Macular Holes
    Interventions
    Inverted ILM Repositioning
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2010-08
    Completion
    2013-08
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Holes
    InterventionInverted ILM Repositioning
    PhaseNot applicable
    Registry statusUnknown

  • Impact of C3F8 or SF6 Use and Length of Face-down Positioning (7 vs 14 Days Respectively) in Macular Hole Surgery

    NCT02073266 · start 2010-01

    Registered record
    Registry ID
    NCT02073266
    Conditions
    Macular Holes; Visual Acuity Gain; Cataract; Complications
    Interventions
    Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-01
    Completion
    2013-05
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMacular Holes; Visual Acuity Gain; Cataract; Complications
    InterventionMacular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.
    PhaseNot applicable
    Registry statusCompleted

  • Triple Therapy for Diffuse Diabetic Macular Edema

    NCT01218750 · start 2008-12

    Registered record
    Registry ID
    NCT01218750
    Conditions
    Diffuse Diabetic Macular Edema
    Interventions
    Triple therapy for diffuse diabetic macular edema
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2008-12
    Completion
    2011-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiffuse Diabetic Macular Edema
    InterventionTriple therapy for diffuse diabetic macular edema
    PhaseNot applicable
    Registry statusUnknown

  • Trypan Blue Versus Brillant Blue for Epiretinal Membranes

    NCT00757380 · start 2008-07

    Registered record
    Registry ID
    NCT00757380
    Conditions
    Idiopathic Epiretinal Membranes
    Interventions
    Trypan Blue; Brillant Blue
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2008-07
    Completion
    2015-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Epiretinal Membranes
    InterventionTrypan Blue; Brillant Blue
    PhaseNot applicable
    Registry statusCompleted

  • Trial of Prognostic Factors and Surgical Methods for the Treatment of Idiopathic Macular Holes

    NCT00302328 · start 2005-08

    Registered record
    Registry ID
    NCT00302328
    Conditions
    Idiopathic Macular Hole
    Interventions
    macular hole operation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2005-08
    Completion
    2009-01
    Enrolment
    78

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Macular Hole
    Interventionmacular hole operation
    PhaseNot applicable
    Registry statusCompleted

  • Indocyanine Green or Trypan Blue for Delamination of the Internal Limiting Membrane in Macular Hole Surgery

    NCT00419185 · start 2003-04

    Registered record
    Registry ID
    NCT00419185
    Conditions
    Idiopathic Macular Hole
    Interventions
    Delamination of the Internal limiting membrane
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-04
    Completion
    2005-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Macular Hole
    InterventionDelamination of the Internal limiting membrane
    PhaseNot applicable
    Registry statusCompleted